Diagonal Bio
0.059 SEK -5.02%Be the first to follow this company
Diagonal Bio operates in the biotechnology industry. The company is developing a platform under the name Panviral to detect and diagnose small sections of pathogen genomes, such as viruses, bacteria, and fungi. In addition to the main business, service and associated ancillary services are also offered. The largest operations take place in Sweden with headquarter in Lund.
Revenue
20K
EBIT %
-57,850 %
P/E
-
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
First North Stockholm
DIABIO
Daily low / high price
0.057 / 0.062
SEK
Market cap
23.48M SEK
Turnover
45.04K SEK
Volume
771K
Financial calendar
Interim report
2024-05-31
General meeting
2024-06-11
Interim report
2024-08-22
Interim report
2024-10-31
Annual report
2025-02-25
Major OwnersSource: Millistream Market Data AB
Owner | Capital | Votes |
---|---|---|
Nordnet Pensionsförsäkring AB | 6.5 % | 6.5 % |
Avanza Pension | 5.7 % | 5.7 % |
Premium
This content is for our Premium customers only.
ShowingAll content types
Diagonal Bio AB announces outcome of rights issue
Diagonal Bio AB: BioStock: Emission ska möjliggöra Diagonal Bios kommersialisering
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools